Latest Earnings Analysis

• Compass Secure (CMPO) Q2 2025: EBITDA Jumps 26% as Operating System Drives Margin Expansion
  August 08, 2025 · CMPO
• Corsair (CRSR) Q2 2025: Components Revenue Jumps 30% as AI and Gaming Upgrade Cycles Accelerate
  August 08, 2025 · CRSR
• Clean Energy Fuels (CLNE) Q2 2025: RNG Volume Jumps 21% as Dairy Ramp and Policy Tailwinds Build
  August 08, 2025 · CLNE
• AMN Healthcare (AMN) Q2 2025: International Nurse Revenue Down $100M From Peak, Setting Up Double-Digit Recovery Path
  August 08, 2025 · AMN
• Akamai (AKAM) Q2 2025: Cloud Infrastructure Services Revenue Jumps 30%, Fueling AI Edge Ambitions
  August 08, 2025 · AKAM
• NGL (NGL) Q1 2026: $19M Debt Repurchase Highlights Opportunistic Capital Deployment
  August 08, 2025 · NGL
• EPLUS (PLUS) Q1 2026: Security Billings Jump 24% as Pure Play Pivot Reshapes Growth Trajectory
  August 08, 2025 · PLUS
• Doximity (DOCS) Q1 2026: SMB Bookings Double as AI Suite Anchors Third Act
  August 08, 2025 · DOCS
• Tegna (MUX) Q2 2025: Cost Actions Deliver 6% Non-Programming Expense Cut as Digital Grows Double Digits
  August 08, 2025 · MUX
• Bridger Aerospace (BAER) Q2 2025: Revenue Doubles on Record Super Scooper Utilization
  August 08, 2025 · BAER
• Corvus Pharmaceuticals (CRVS) Q2 2025: $35.7M Warrant Exercise Extends Cash Runway Into 2026
  August 08, 2025 · CRVS
• SandRidge Energy (SD) Q2 2025: Oil Output Jumps 46%, Cherokee Wells Anchor Multi-Year Upside
  August 08, 2025 · SD
• CyTOMICS (CTMX) Q2 2025: $100M Raise Extends Runway, CX2051 Data Sets Stage for CRC Push
  August 08, 2025 · CTMX
• Atea Pharmaceuticals (AVIR) Q2 2025: $25M Buyback and Phase III HCV Trials Advance Toward $3B Market
  August 08, 2025 · AVIR
• LifeCorps (LFCR) Q4 2025: 11 Late-Stage Programs Signal Pipeline Inflection Ahead
  August 08, 2025 · LFCR
• AMTX Q2 2025: LCFS Credit Price Jumps 50% Unlock Multi-Segment Cash Flow Upside
  August 08, 2025 · AMTX
• Monster Beverage (MNST) Q2 2025: International Sales Jump 16.5%, Ultra Brand Drives Category Outperformance
  August 08, 2025 · MNST
• Vistagen Therapeutics (VTGN) Q1 2026: R&D Spend Jumps 54% as Palisade Trials Near Data Catalyst
  August 08, 2025 · VTGN
• Natera (NTRA) Q2 2025: Signatera Volumes Jump 20,000 Units, Fueling $80M Guidance Raise
  August 08, 2025 · NTRA
• Kura Oncology (KURA) Q2 2025: $630M Cash Anchors Zipdementib Launch and Phase III Acceleration
  August 08, 2025 · KURA
• ImmuneBio (INMB) Q2 2025: $16.5M Asset Write-Off Signals Strategic Reset on ExPro Path
  August 08, 2025 · INMB
• SCPH Q2 2025: Ferosix Unit Shipments Jump 45% as Nephrology Uptake Accelerates
  August 08, 2025 · SCPH
• Inuvo (INUV) Q2 2025: Self-Serve Client Count Jumps 300% as Margin Mix Shifts
  August 08, 2025 · INUV
• FiscalNote (NOTE) Q2 2025: Adjusted EBITDA Margin Jumps to 12% as PolicyNote Adoption Accelerates
  August 08, 2025 · NOTE
• Sky Bioscience (SKYE) Q2 2025: $9.1M Manufacturing Spend Signals Acceleration Toward Phase 2b Obesity Data
  August 08, 2025 · SKYE
• Willdan (WLDN) Q2 2025: Organic Growth Hits 23%, Cross-Selling and Data Center Demand Accelerate Pipeline
  August 08, 2025 · WLDN
• PKST Q2 2025: iOS ABR Jumps 25% as Office Exit Accelerates
  August 08, 2025 · PKST
• 2Cows (TCX) Q2 2025: Domains Migration Adds 10M+ TLDs, Accelerating Margin Expansion Path
  August 08, 2025 · TCX
• JYNT Q2 2025: Refranchising Cuts Corporate Clinics to 8%, Unlocks Margin and Capital Flexibility
  August 08, 2025 · JYNT
• HASI Q2 2025: Pipeline Surges Past $6B, Capital Efficiency Triples with CCH1
  August 08, 2025 · HASI
• Cidara Therapeutics (CDTX) Q2 2025: $402M Cash Infusion Extends Phase 3 Runway for CD388
  August 08, 2025 · CDTX
• PACB Q2 2025: Vega Adds 40+ New Labs, Driving 53% APAC Growth and Expanding Clinical Adoption
  August 08, 2025 · PACB
• BZFD Q2 2025: Studio Revenue Quadruples, Driving Business Model Reset
  August 08, 2025 · BZFD
• StepStone (STEP) Q1 2026: Fee-Earning Assets Jump $6B, Private Wealth Now 8% of Earnings
  August 08, 2025 · STEP
• Grove Collaborative (GROV) Q2 2025: Sequential Orders Rise 3.4% as Platform Migration Stabilizes
  August 08, 2025 · GROV
• Definitive Healthcare (DH) Q2 2025: Retention Rate Hits 12-Month High, Margin Discipline Sustains Cash Flow
  August 08, 2025 · DH
• GEN (GEN) Q1 2026: MoneyLion Powers 45% Growth, Shifting GEN Into Double-Digit Expansion
  August 08, 2025 · GEN
• Alta Equipment Group (ALTG) Q2 2025: $50M Rental Fleet Reduction Drives Leaner EBITDA Mix
  August 08, 2025 · ALTG
• CTSO Q2 2025: German Sales Jump 22% as Regulatory Appeals Shape Near-Term Trajectory
  August 08, 2025 · CTSO
• Adtalem (ATGE) Q4 2025: Walden Enrollment Up 15% as Healthcare Education Demand Accelerates
  August 08, 2025 · ATGE
• DocGo (DCGO) Q2 2025: Medical Transport Rises to 62% of Revenue as Migrant Wind-Down Reshapes Mix
  August 08, 2025 · DCGO
• Yelp (YELP) Q2 2025: AI Search API Usage Jumps 10x, Unlocking New Monetization Pathways
  August 08, 2025 · YELP
• Eventbrite (EB) Q2 2025: Eventbrite Ads Grows 50%, Offsetting Ticket Volume Lag
  August 08, 2025 · EB
• Texas Roadhouse (TXRH) Q2 2025: Beef Inflation Hits 7%, Margin Pressures Mount Despite Traffic Gains
  August 08, 2025 · TXRH
• NERDY (NRDY) Q2 2025: ARPUM Jumps 24% as LivePlus AI Drives Retention and Margin Upside
  August 08, 2025 · NRDY
• Lionsgate Studios (LION) Q1 2026: Library Revenue Climbs 12%, Anchoring Two-Year Growth Reset
  August 08, 2025 · LION
• Arlo (ARLO) Q2 2025: Subscriptions Hit 60% of Revenue, Powering 800bp Margin Expansion
  August 08, 2025 · ARLO
• nLIGHT (LASR) Q2 2025: Amplifier Ramp Drives 40% A&D Growth, Unlocks Manufacturing Leverage
  August 08, 2025 · LASR
• Array Technologies (ARRY) Q2 2025: New Products Drive 35% of Order Book as Margin Mix Shifts
  August 08, 2025 · ARRY
• Inogen (INGN) Q2 2025: B2B Revenue Jumps 19%, Expanding Addressable Market with VOXI5 Launch
  August 08, 2025 · INGN